CN103599123A - Drug for treating purine metabolic disorder disease - Google Patents
Drug for treating purine metabolic disorder disease Download PDFInfo
- Publication number
- CN103599123A CN103599123A CN201310645221.XA CN201310645221A CN103599123A CN 103599123 A CN103599123 A CN 103599123A CN 201310645221 A CN201310645221 A CN 201310645221A CN 103599123 A CN103599123 A CN 103599123A
- Authority
- CN
- China
- Prior art keywords
- treating
- hyperuricemia
- drug
- structural formula
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a drug for treating purine metabolic disorder disease, provides a flavonoids compound represented by the formula (I) and a modified derivative thereof, and a use in inhibition of xanthine oxidase activity and promotion of uric acid excretion function, wherein R1, R2 and R3 independently represent -H or monosaccharide residues, and R4 represents -H or -OH. In particular, the drug is used for treating purine metabolic disorder disease, and can be used for treating hyperuricemia and related diseases and reducing a individual serum UA level; the drug is used for treating hyperuricemia; the drug is used for treating the related diseases, such as for treating gouty arthritis and arthrophlogosis caused by hyperuricemia, and for treating chronic interstitial nephritis, kidney stones and the like caused by hyperuricemia. The drug has the advantages of natural chemical structure, safety, low toxicity, rapid curative effect and fewer side effects. (I).
Description
Technical field
The present invention relates to technical field of pharmaceuticals, specifically, relate to the application of a kind of flavone compound and modified derivative thereof and be used for the treatment of the medicine of purine metabolic disturbance disease.
Background technology
From the epidemic data of European and American developed countries and China, the morbidity of hyperuricemia (HUA) is the trend rising year by year.Along with the raising of people's living standard, dietary structure tends to high fat, high protein aspect changes.In China, not only there is the situation improving with living standard in the morbidity of hyperuricemia, and the morbidity of hyperuricemia is the trend of becoming younger.
Hyperuricemia refer to that the generation of the serum uric acid (UA) that human body causes due to purine metabolic disturbance increases and (or) a kind of disease of reducing of excretion.Under normal purine diet state, non-twice horizontal male of Diagnostic Value of Fasting Serum UA is higher than 420mmol/L on the same day, and women, higher than 360mmol/L, is called hyperuricemia.UA depends on the equilibrium relation of formation speed and the drainage rate of UA in the concentration of extracellular fluid.Though UA generates to increase or drain, reduce or excretion does not subtract but generates to surpass and drains, all can make UA accumulate and occur hyperuricemia.Gout is the crystal dependency arthrosis due to a kind of monosodium urate salt (MSU) deposition, with purine metabolic disturbance and (or) hyperuricemia of UA excretion due to reducing be directly related, belongs to metabolic rheumatism category.It is most important biochemical basis and the most direct risk factor that gout occurs that serum UA raises.
Hyperuricemia is not only the important biochemical basis that causes gout, and closely related with the generation of hypertension, hyperlipemia, atherosclerosis, obesity, insulin resistant.
Patients with Hyperuricemia is for a long time when high UA state, and the crystallization of UA salt will be in tissue and organ deposition.Its clinical manifestation is that hyperuricemia and the gouty arthritis that causes are therefrom shown effect repeatedly, tophus deposition, tophus chronic arthritis and joint deformity, kidney urate calculus and (or) gouty excess of the kidney matter pathological changes, and above-mentioned pathological changes can exist alone or in combination.But hyperuricemia can not be equal to gout, the two is not only had any different but also be related, can, two different phases regarding as with hyperuricemia and gout in disease progression process, there is no strict boundary between the two.
From clinical drug treatment, require, the major requirement of control primary disease reaches following object: stop as early as possible acute arthritis outbreak; Prevent arthritis recurrence; Correct hyperuricemia, control UA mineralization is in caused diseases such as kidney, joints; Prevent that uric acid renal calculus from forming.Make a general survey of both at home and abroad, the medicine for the treatment of has Western medicine and Chinese medicine clinically at present.Western medicine mainly contains the medicines such as colchicine, Tai Song or crovaril, indometacin, ibuprofen, piroxicam, naproxen, prednisone, benemid, sulphinpyrazone, benzbromarone, allopurinol, but all with more side effect.Chinese medicine aspect mainly contains gout relaxing tablet, gout stator, pain relieving rheumatism ball, TONGFENGDING capsule etc., but, from ingredient, substantially all by medical herbs crude extract collocation such as Semen Coicis, Cortex Phellodendri, Radix Achyranthis Bidentatae, Rhizoma Atractylodis, Rhizoma Smilacis Glabrae, Rhizoma Dioscoreae Septemlobae, Radix Stephaniae Tetrandrae, Semen Plantaginis, Rhizoma Alismatis, Caulis Lonicerae, Radix Paeoniae Rubra, Radix Clematidis, Radix Angelicae Sinensis, Radix Gentianae Macrophyllae, Poria, Pheretima, Fructus Chaenomelis, Radix Glycyrrhizaes, formed.From curative effect, Chinese Herbs do not have Western medicine curative effect fast, the course for the treatment of is longer.
So, it is active and promote the flavone compound of uric acid (UA) Excretion and the application of modified derivative thereof that research has inhibition xanthine oxidase (XOD), and exploitation have natural exist structure, safety, low toxicity, curative effect fast, the medicine of the treatment hyperuricemia of few side effects is significant.
Summary of the invention
The object of the invention is for the problems referred to above, provide a kind of have suppress xanthine oxidase activity and promote the flavone compound of urate excretion effect and the application of modified derivative and have native chemical structure, safety, low toxicity, curative effect fast, the medicine that is used for the treatment of purine metabolic disturbance disease of few side effects.
The present invention, provides the flavone compound shown in (I) that has structural formula and modified derivative thereof for suppressing xanthine oxidase activity and promoting the active purposes of urate excretion;
（I）
Wherein: R
1, R
2, R
3be independently of one another-H or monosaccharide residue; R
4for-H or-OH; Dotted line represents to have or does not have two keys.
The present invention, provides the flavone compound shown in (I-a) that has structural formula and modified derivative thereof for suppressing xanthine oxidase activity and promoting the active purposes of urate excretion; It between C2-C3, is singly-bound; Described R
1for-H or rhamnose (Rha) residue, R
2, R
3be independently of one another-H R
4for-H or-OH;
（I-a）；
More specifically, select the astilbin of following structural formula (I-1), the naringenin of following structural formula (I-2):
（I-1），
（I-2）。
The present invention, provides the flavone compound shown in (I-b) that has structural formula and modified derivative thereof for suppressing xanthine oxidase activity and promoting the active purposes of urate excretion; Between C2-C3, be two keys; Described R
1, R
4be independently of one another-H R
2for glucose (Glc) residue, R
3for-H or xylose (Xyl) residue;
（I-b）；
More specifically, select the Schaftoside of following structural formula (I-3), the Saponaretin of following structural formula (I-4):
（I-3），
（I-4）。
The present invention, the pharmaceutical composition of the activated structural formula of tool (I) and modified derivative thereof, has one or more reactive compounds and acceptable carrier pharmaceutically, is used for the treatment of purine metabolic disturbance disease.Particularly, can be used for the treatment of hyperuricemia and relevant disease, the individual serum UA of reduction level.Be used for the treatment of hyperuricemia; Being used for the treatment of relevant disease comprises gout, the arthritis that is used for the treatment of metabolic arthritis and causes and is used for the treatment of chronic interstitial nephritis that metabolic arthritis causes, renal calculus etc.
The present invention, the hyperuricemia for the treatment of comprises idiopathic hyperuricemia and insecondary hyperuricemia.
The present invention, the antihyperuricemic disease for the treatment of includes but not limited to that hyperuricemia causes that gouty acute arthritis is shown effect repeatedly, tophus forms, tophus arthritis and joint deformity, involve kidney and cause that chronic interstitial nephritis and uric acid renal calculus form.
The present invention, when medicine and pharmacology use, can contain and meet one or more compounds of structural formula flavone compound shown in (I) and modified derivative thereof and become pharmaceutical composition with acceptable vehicle group pharmaceutically; Be that aforementioned pharmaceutical compositions preparation includes but not limited to the preparation that the new techniques such as the preparations such as tablet, injection, capsule, pill, syrup, granule, tincture, oral suspensions, Orally taken emulsion, powder and controlled release, liposome, microemulsion, microsphere microcapsule carrier, nanoparticle, Echogenic Microbubbles, microelectron-mechanical drug administration carrier, self-emulsifying drug transmission, mucosal drug delivery, percutaneous dosing, target administration are made.
The preparation that the pharmaceutical composition that the present invention forms is made can be for aspects such as medicine and health product.
Provided by the present inventionly meet the flavone compound shown in structural formula (I) and modified derivative can extract and obtain from natural herb plant (as Rhizoma Smilacis Glabrae, Herba Desmodii Styracifolii, Herba Lysimachiae, Rhizoma Alismatis etc.), also can use suitably semi-synthetic or synthetic method to obtain.
The present invention, proves by lot of experiments, and medicine of the present invention is the medicine with the treatment hyperuricemia of safety, low toxicity.And medicament sources is abundant, low price, be not subject to the restriction of the natural conditions such as region, season.No matter medicine of the present invention is preparation oral administration or drug administration by injection if being made preparation, treatment hyperuricemia and relevant intercurrent disease, the individual serum UA of reduction level are had to very significant curative effect.
So the present invention, has outstanding substantive distinguishing features and significant good effect.
The present invention, the flavone compound shown in formula (I) and modified derivative thereof have and suppress xanthine oxidase activity and promote urate excretion effect, medicine have advantages of native chemical structure, safety, low toxicity, curative effect fast, few side effects.
The present invention is further illustrated for embodiment below.
The specific embodiment
The astilbin of take is described in further detail content of the present invention as embodiment:
（I-1）。
Embodiment 1: each solvent position of Rhizoma Smilacis Glabrae suppresses the situation of XOD activity
Detect principle: XOD catalysis xanthine generates UA, UA and NBT(NBT) react raw empurpled first and (formazan), after the activity of XOD is suppressed, the UA amount generating reduces, the first of purple and generating also just reduces thereupon, by under 560nm, measure the purple first that generates and absorbance detect the size that suppresses active.
The preparation of sample: get rhizoma smilacis glabrae medicinal material 100g, coarse crushing, crosses 40 mesh sieves, measures 50% ethanol percolate extraction 3 times by 15 times of amounts, 10 times of amounts, 5 times, and merging percolate, is recycled to without alcohol taste, with distilled water, is settled to 250ml, is Rhizoma Smilacis Glabrae sample solution.Measure Rhizoma Smilacis Glabrae sample 25ml and be placed in separatory funnel, use successively petroleum ether, chloroform, ethyl acetate and n-butanol extraction, evaporate to dryness respectively, to 25ml, obtains petroleum ether part, chloroform extract, ethyl acetate extract, n-butanol portion and water position sample with dmso solution standardize solution.
Blank XOD determination of activity: draw in 50mmol/L phosphate buffer 3ml to 10ml volumetric flask, then add respectively 3ml xanthine solution (2.0mmol/L) and 0.4mlNBT(1.8mg/L), shake up, be XOD determination of activity blank solution.Toward this blank solution, add 2.5mlXOD solution (0.08U/ml) to shake up again, be XOD determination of activity solution.With XOD solution add beginning timing, after 25 ℃ of reaction 30min, under 560nm wavelength, take blank solution as contrast, measure XOD absorbance A
0.
Each sample solution is measured the inhibitory action of XOD activity: accurate absorption in " preparation of sample " item respectively extracts position solution solution to be measured 0.5ml, respectively be placed in 10ml volumetric flask, by " blank XOD determination of activity " lower operation, obtain respectively sample XOD inhibition determination of activity and suppress determination of activity XOD solution with blank solution and sample XOD.With XOD solution add beginning timing, after 25 ℃ of reaction 30min, under 560nm wavelength, take blank solution as contrast, measure XOD absorbance A
x.
Each solvent position of table 1 Rhizoma Smilacis Glabrae suppresses XOD determination of activity result
The inhibition measurement result of XOD activity is as shown in table 1, and each position inhibition is sequentially ethyl acetate extract solution suppression ratio > Rhizoma Smilacis Glabrae sample solution suppression ratio > > water position solution suppression ratio ≈ petroleum ether part solution suppression ratio ≈ n-butanol portion solution suppression ratio ≈ chloroform extract solution suppression ratio.Wherein Rhizoma Smilacis Glabrae sample has stronger inhibitory action to activity, and in each extraction position, ethyl acetate extract is the strongest to active inhibitory action, and surpasses Rhizoma Smilacis Glabrae sample.The effect that ethyl acetate extract suppresses XOD activity is better than crude drug, shows that the material base that suppresses XOD activity in rhizoma smilacis glabrae medicinal material mainly concentrates in ethyl acetate extract.Through flavones content analysis, show, Rhizoma Smilacis Glabrae flavones ingredient is the effective site that suppresses XOD activity.Through mass spectrum and contrast liquid phase analysis, confirmed in flavone position containing astilbin the highlyest, also have in addition a small amount of naringenin, 2-(3,4-hydroxy phenyl)-3,4-dihydro-2H-1-.alpha.-5:6-benzopyran-3, the flavone compounds such as 5,7-triol.
Embodiment 2: the extraction and purification of astilbin in Rhizoma Smilacis Glabrae
Get rhizoma smilacis glabrae medicinal material 100g, coarse crushing, cross 40 mesh sieves, with 15 times of amounts, 10 times of amounts, 5 times of amount 50% ethanol percolate extraction 3 times, merge percolate, concentrated (30 ℃, d=1.15-1.20), add 2 times of long-pending amount 95% ethanol of concentrated liquid, stir and produce after flocculent deposit in 4 ℃ of standing 12h of refrigerator, afterwards centrifugal 30min under 4000r/min condition.Get supernatant, rotary evaporation is removed ethanol.With appropriate petroleum ether, clean 2 times again, dry, add 50% ethanol 500ml and dissolve, adopt polyamide purification via adsorption-based process.Water, 10% ethanol, 50% ethanol are eluent respectively, collect 50% ethanol elution, and concentrated evaporate to dryness, obtains faint yellow material.Through NMR, SM, IR and UV spectrum analysis, this thing is astilbin (3
, , 4
, , 5,7-kaempferol-3-rhamnoside).
Embodiment 3: on hyperuricemia rat blood serum UA and the active impact suppressing of XOD.
Testing all rats is SD rat, wherein female male half and half.Totally 80, body weight 200-240g.Get 80 of rats, be divided at random totally 4 groups of blank group, model group, medicine group and colchicine groups, 20 every group.Except blank group, all the other each groups were with the modeling of adenine 100mg/kg gavage, continuous one week.5d starts respectively medicine group and colchicine group gastric infusion astilbin 40mg/kg and colchicine 40mg/kg, continuously 5d.Blank group and model group be the isopyknic distilled water of gavage respectively, and each group is all by 0.25ml/25g body weight gavage.At experiment 10d, 1h after administration, each treated animal is plucked eyeball and is got blood, the activity of UA and XOD in mensuration rat blood serum.
Test data with mean standard deviation (
± s) represent, adopt the analysis of SPSS11.5 statistical package, relatively use one factor analysis of variance method between group, significance level is with P < 0.05 and P < 0.01 standard.Following examples adopt identical analytic process.
The impact of table 2 hyperuricemia rat model UA and XOD activity
As can be seen from Table 2, compare with blank group, in model group rat blood serum, UA level and XOD activity all have significantly and increase (P < 0.01).By contrast model group, the UA level of each group of medicine group and colchicine group and XOD activity all have decline (P < 0.05) in various degree, and the Amplitude Ratio colchicine group of medicine group reduction is large.Above analytic explanation medicine group is conducive to suppress the activity of XOD and reduce UA level, and the treatment of hyperuricemia is had to positive effect.
Embodiment 4: the diuresis to large mouse with renal calculs
Testing all rats is SD rat, wherein female male half and half.Totally 60, body weight 200-240g.60 rats are divided into 3 groups at random: blank group, medicine group and frusemide group, 20 every group.Test is carried out through 1 month modeling Cheng Shihou.Animal fasting be can't help after water 12h, each organize rat all with normal saline by 30ml/kg lumbar injection.To medicine group and frusemide group gavage astilbin 40mg/kg and frusemide 50mg/kg immediately, administration volume is 20ml/kg respectively, and blank group gives equal-volume distilled water.With hand, compeling rat hypogastric region drains all the other urine.Immediately single rat is put in people's metabolic cage.3rd, 6, after 9h, to every rat, give again respectively the warm water of 50ml/kg25-30 ℃ at every turn.Collect each animal 0-15h urine side and determine voided volume.
Diuresis (the unit: ml) of the different groups of table 3 to rat water load
As can be seen from Table 3, and the comparison of blank group, medicine group and matched group all can significantly increase the voided volume (P < 0.05) of rat, be beneficial to the discharge of lithangiuria, and medicine group are more remarkable.
embodiment 5: the impact on hyperuricemia rat blood serum cholesterol, creatinine, urea nitrogen levels, triglyceride (TG) content.
Testing all rats is SD rat, wherein female male half and half.Totally 80, body weight 200-240g.Get 80 of rats, be divided at random totally 4 groups of blank groups, model group, medicine group, colchicine group, 20 every group.Except blank group, all the other each groups were with the modeling of adenine 100mg/kg gavage, continuous one week.5d starts respectively medicine group and colchicine group gastric infusion astilbin 40mg/kg and colchicine 40mg/kg, continuously 5d.Blank group and model group be the isopyknic distilled water of gavage respectively, and each group is all by 0.25ml/25g body weight gavage.At experiment 10d, 1h after administration, each treated animal is plucked eyeball and is got blood, measures rat blood serum cholesterol, creatinine, urea nitrogen levels, content of triglyceride.
As can be seen from Table 4, compare with blank group, model group is no matter be cholesterolemia and serum creatinine, or blood urea nitrogen and blood triglyceride, has remarkable increase (P < 0.01); By model group and medicine group, compare, cholesterolemia in medicine group, serum creatinine and blood triglyceride all slightly reduce, and blood urea nitrogen significantly decreases, and also lower than the blood urea nitrogen of blank group, illustrate that medicine causes various Developmental and Metabolic Disorder all to have protective effect to uric acid disease; From table 4, can also learn, colchicine group creatinine numerical value, triglyceride numerical value and blood urea nitrogen numerical value are all high than model group numerical value in various degree, thereby show while taking colchicine for hyperuricemia, relatively large to the damage of renal function.
The impact of table 4 hyperuricemia rat model cholesterol, creatinine, urea nitrogen levels, content of triglyceride
The astilbin of take is above described in further detail content of the present invention as embodiment, but this should be interpreted as to the scope of the above-mentioned theme of the present invention only limits to following example.All technology realizing based on foregoing of the present invention all belong to scope of the present invention.
Those skilled in the art can use for reference content herein, suitably improve technological parameter and realize.Special needs to be pointed out is, all similar replacements and change are easy to do for a person skilled in the art, and they are all deemed to be included in the present invention.Product of the present invention and application are described by preferred embodiment, related personnel obviously can change methods and applications as herein described or suitably change and combination within not departing from content of the present invention, spirit and scope, realizes and apply the technology of the present invention.
Claims (9)
1. flavone compound and modified derivative thereof shown in formula (I), for suppressing xanthine oxidase activity and promoting the active purposes of urate excretion;
（I）
Wherein: R
1, R
2, R
3be independently of one another-H or monosaccharide residue; R
4for-H or-OH; Dotted line represents to have or does not have two keys.
2. according to the purposes described in claim 1, it is characterized in that: described R
1for-H or rhamnose (Rha) residue, R
2, R
3be independently of one another-H R
4for-H or-OH; Be selected from structural formula (I-a):
（I-a）。
3. according to the purposes described in claim 1, it is characterized in that: described R
1, R
4be independently of one another-H R
2for glucose (Glc) residue, R
3for-H or xylose (Xyl) residue; Be selected from structural formula (I-b):
（I-b）。
4. purposes according to claim 2, is characterized in that: described flavone compound and modified derivative thereof have the structural formula that is selected from lower group:
（I-1）， （I-2）。
5. purposes according to claim 3, is characterized in that: described flavone compound and modified derivative thereof have the structural formula that is selected from lower group:
（I-3）， （I-4）。
6. a pharmaceutical composition with structural formula described in claim 1,2,3,4 or 5, it is characterized in that: there is the composition of structural formula described in one or more claim 1,2,3,4 or 5 and acceptable carrier pharmaceutically, be used for the treatment of purine metabolic disturbance disease.
7. pharmaceutical composition according to claim 6, is characterized in that: be used for the treatment of hyperuricemia.
8. pharmaceutical composition according to claim 6, is characterized in that: be used for the treatment of gout, arthritis that metabolic arthritis causes.
9. pharmaceutical composition according to claim 6, is characterized in that: be used for the treatment of chronic interstitial nephritis, renal calculus that metabolic arthritis causes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310645221.XA CN103599123B (en) | 2013-12-03 | 2013-12-03 | A kind of medicine for the treatment of purine metabolic disorder disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310645221.XA CN103599123B (en) | 2013-12-03 | 2013-12-03 | A kind of medicine for the treatment of purine metabolic disorder disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103599123A true CN103599123A (en) | 2014-02-26 |
| CN103599123B CN103599123B (en) | 2016-03-02 |
Family
ID=50117432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310645221.XA Active CN103599123B (en) | 2013-12-03 | 2013-12-03 | A kind of medicine for the treatment of purine metabolic disorder disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103599123B (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105085498A (en) * | 2015-06-19 | 2015-11-25 | 武汉光谷人福生物医药有限公司 | Method and system for extraction and separation of isovitexin from Desmodium styracifolium |
| WO2015188609A1 (en) * | 2014-06-09 | 2015-12-17 | 苏州凯祥生物科技有限公司 | New use of a benzopyran derivative in preparation of medicament for treating hyperuricemia |
| CN106421047A (en) * | 2016-11-07 | 2017-02-22 | 华南理工大学 | Honey pomelo leaf extract, preparation method thereof and application |
| CN108404004A (en) * | 2018-04-17 | 2018-08-17 | 江西中医药大学 | A kind of Rhizoma Smilacis Glabrae extract and its preparation method and application |
| CN108619120A (en) * | 2018-07-09 | 2018-10-09 | 广东省微生物研究所（广东省微生物分析检测中心） | Purposes of 2`, the 5`- resacetophenone in the drug for preparing anti-trioxypurine relevant disease |
| WO2020031961A1 (en) * | 2018-08-10 | 2020-02-13 | サントリーホールディングス株式会社 | Composition for promoting uric acid excretion, composition for inhibiting urat1 and composition for lowering blood uric acid level |
| CN112791003A (en) * | 2021-01-26 | 2021-05-14 | 上海澄穆生物科技有限公司 | Use of retinoic acid receptor agonist compounds in cosmetic compositions |
| CN115707464A (en) * | 2021-08-19 | 2023-02-21 | 北京大学 | Inhibition of schaftoside on novel coronavirus main protease and medicinal application thereof |
| CN116549537A (en) * | 2023-06-08 | 2023-08-08 | 北京罗诺强施医药技术研发中心有限公司 | Stable compositions and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101804064A (en) * | 2010-04-08 | 2010-08-18 | 成都军区昆明总医院 | Application of dihydroquercetin and glucoside compounds to preparing drug-resistance bacteria medicine |
| CN101879264A (en) * | 2009-05-05 | 2010-11-10 | 戴永青 | Chinese medicinal composition for reducing blood uric acid |
-
2013
- 2013-12-03 CN CN201310645221.XA patent/CN103599123B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101879264A (en) * | 2009-05-05 | 2010-11-10 | 戴永青 | Chinese medicinal composition for reducing blood uric acid |
| CN101804064A (en) * | 2010-04-08 | 2010-08-18 | 成都军区昆明总医院 | Application of dihydroquercetin and glucoside compounds to preparing drug-resistance bacteria medicine |
Non-Patent Citations (1)
| Title |
|---|
| 徐婷婷 等: "土茯苓抑制黄嘌呤氧化酶活性的物质基础研究", 《中药材》, vol. 35, no. 4, 30 April 2012 (2012-04-30), pages 582 - 585 * |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015188609A1 (en) * | 2014-06-09 | 2015-12-17 | 苏州凯祥生物科技有限公司 | New use of a benzopyran derivative in preparation of medicament for treating hyperuricemia |
| CN105311011A (en) * | 2014-06-09 | 2016-02-10 | 苏州凯祥生物科技有限公司 | Novel application of benzopyran derivative in preparation of drug for treating hyperuricaemia |
| CN105085498B (en) * | 2015-06-19 | 2018-11-02 | 武汉光谷人福生物医药有限公司 | The method and system of extraction separation isovitexin from Desmodium styracifolium |
| CN105085498A (en) * | 2015-06-19 | 2015-11-25 | 武汉光谷人福生物医药有限公司 | Method and system for extraction and separation of isovitexin from Desmodium styracifolium |
| CN106421047A (en) * | 2016-11-07 | 2017-02-22 | 华南理工大学 | Honey pomelo leaf extract, preparation method thereof and application |
| CN106421047B (en) * | 2016-11-07 | 2020-09-22 | 华南理工大学 | Honey pomelo leaf extract and preparation method and application thereof |
| CN108404004A (en) * | 2018-04-17 | 2018-08-17 | 江西中医药大学 | A kind of Rhizoma Smilacis Glabrae extract and its preparation method and application |
| CN108619120A (en) * | 2018-07-09 | 2018-10-09 | 广东省微生物研究所（广东省微生物分析检测中心） | Purposes of 2`, the 5`- resacetophenone in the drug for preparing anti-trioxypurine relevant disease |
| WO2020031961A1 (en) * | 2018-08-10 | 2020-02-13 | サントリーホールディングス株式会社 | Composition for promoting uric acid excretion, composition for inhibiting urat1 and composition for lowering blood uric acid level |
| CN112566514A (en) * | 2018-08-10 | 2021-03-26 | 三得利控股株式会社 | Composition for promoting uric acid excretion, composition for inhibiting URAT1, and composition for lowering uric acid level in blood |
| JPWO2020031961A1 (en) * | 2018-08-10 | 2021-08-12 | サントリーホールディングス株式会社 | Composition for promoting uric acid excretion, composition for inhibiting URAT1 and composition for lowering blood uric acid level |
| JP7307073B2 (en) | 2018-08-10 | 2023-07-11 | サントリーホールディングス株式会社 | Composition for promoting uric acid excretion, composition for inhibiting URAT1 and composition for reducing blood uric acid level |
| CN112791003A (en) * | 2021-01-26 | 2021-05-14 | 上海澄穆生物科技有限公司 | Use of retinoic acid receptor agonist compounds in cosmetic compositions |
| CN115707464A (en) * | 2021-08-19 | 2023-02-21 | 北京大学 | Inhibition of schaftoside on novel coronavirus main protease and medicinal application thereof |
| CN116549537A (en) * | 2023-06-08 | 2023-08-08 | 北京罗诺强施医药技术研发中心有限公司 | Stable compositions and uses thereof |
| CN116549537B (en) * | 2023-06-08 | 2024-02-27 | 北京罗诺强施医药技术研发中心有限公司 | Stable compositions and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103599123B (en) | 2016-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103599123B (en) | A kind of medicine for the treatment of purine metabolic disorder disease | |
| CN1931270B (en) | Sobering up and liver protecting Chinese medicine preparation and its preparation process | |
| CN101816723A (en) | Sobering up and liver protecting Chinese medicinal preparation and preparation method thereof | |
| CN101744986B (en) | Extraction method for ginseng, ophiopogon root and schisandra chinensis and preparation thereof | |
| CN101744993B (en) | Extraction method for ginseng, ophiopogon root and schisandra chinensis and preparation thereof | |
| CN101745012B (en) | Method for extracting ginseng, dwarf lilyturf tuber and schisandra chinensis and preparation thereof | |
| CN101744991B (en) | Single extraction method of ginseng, ophiopogon root and shiandra and preparation thereof | |
| CN101745008B (en) | Extraction method of ginseng, ophiopogon root and shiandra and preparation thereof | |
| CN101745011B (en) | Method for extracting ginseng, dwarf lilyturf tuber and schisandra chinensis and preparation thereof | |
| CN101744997B (en) | Extraction method of ginseng, ophiopogon root and shiandra and preparation thereof | |
| CN101744996B (en) | Extraction method of ginseng, ophiopogon root and shiandra and preparation thereof | |
| CN101744989B (en) | Method for extracting schisandra chinensis, ginseng and dwarf lilyturf root and preparation thereof | |
| CN101744990B (en) | Method for individually extracting ginseng, radix ophiopogonis and schisandra chinensis and preparation thereof | |
| CN101744999B (en) | Extraction method for ginseng, ophiopogon root and schisandra chinensis and preparation thereof | |
| CN101745010B (en) | Extraction method of ginseng, ophiopogon root and shiandra and preparation thereof | |
| CN101745005B (en) | Extraction method of ophiopogon root, ginseng and shiandra and preparation thereof | |
| CN101745006B (en) | Extraction method of ophiopogon root, ginseng and shiandra and preparation thereof | |
| CN101744995B (en) | Method for extracting ginseng, dwarf lilyturf tuber and schisandra chinensis and preparation thereof | |
| CN101744998B (en) | Extraction method of ginseng, ophiopogon root and shiandra and preparation thereof | |
| CN101744988B (en) | Method for extracting ginseng, dwarf lilyturf tuber and schisandra chinensis and preparation thereof | |
| CN104688934A (en) | Composition of Pu'er tea effective component and application of composition in preparation of medicine or health food for reducing fat | |
| CN101745003B (en) | Extraction method of ophiopogon root, ginseng and shiandra and preparation thereof | |
| CN101744992B (en) | Extraction method of ginseng, ophiopogon root and schisandra chinensis and preparation thereof | |
| CN101744987A (en) | Single extraction method of ginseng, ophiopogon root and shiandra and preparation thereof | |
| CN101744994A (en) | Extraction method for ginseng, ophiopogon root and schisandra chinensis and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: LUO GUANDI Free format text: FORMER OWNER: GUANGDONG SHIXIN PHARMACEUTICAL CO., LTD. Effective date: 20150513 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20150513 Address after: 510070 room 12, building 91, 601 Zhuang Road, Tianhe District, Guangdong, Guangzhou, Dongguan Applicant after: Luo Guandi Address before: 515500 green industrial park, Jiedong Development Zone, Jieyang, Guangdong Applicant before: Guangdong Shixin medcine Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20181009 Address after: 515500 Green Industrial Park, Jiedong Economic Development Zone, Jieyang, Guangdong Patentee after: Guangdong Shixin medcine Co., Ltd. Address before: 510070 601 building, 91 Dongguan Zhuang Road, Tianhe District, Guangzhou, Guangdong, China, 12 Patentee before: Luo Guandi |
|
| TR01 | Transfer of patent right |